TrialPloS one2019

First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis.

Lutz Renders et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.